Raphael Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2019
Selling, General & Admin	0.61	0.73	0.76	2.14	0.85	Upgrade
Research & Development	0.63	0.78	0.57	1.18	0.78	Upgrade
Operating Expenses	1.25	1.51	1.33	3.32	1.63	Upgrade
Operating Income	-1.25	-1.51	-1.33	-3.32	-1.63	Upgrade
Interest Expense	-0.02	-	-	-	-	Upgrade
Currency Exchange Gain (Loss)	-0.02	-0.01	-0.01	-0.04	0.01	Upgrade
Other Non Operating Income (Expenses)	-0	-0	-0	-0	-0	Upgrade
Pretax Income	-1.28	-1.52	-1.34	-3.36	-1.62	Upgrade
Net Income	-1.28	-1.52	-1.34	-3.36	-1.62	Upgrade
Net Income to Common	-1.28	-1.52	-1.34	-3.36	-1.62	Upgrade
Shares Outstanding (Basic)	20	19	17	14	11	Upgrade
Shares Outstanding (Diluted)	20	19	17	14	11	Upgrade
Shares Change (YoY)	4.70%	11.71%	16.56%	28.37%	18.10%	Upgrade
EPS (Basic)	-0.07	-0.08	-0.08	-0.23	-0.15	Upgrade
EPS (Diluted)	-0.07	-0.08	-0.08	-0.23	-0.15	Upgrade
Free Cash Flow	-0.21	-0.53	-1.2	-0.76	-1.42	Upgrade
Free Cash Flow Per Share	-0.01	-0.03	-0.07	-0.05	-0.13	Upgrade
EBIT	-1.25	-1.51	-1.33	-3.32	-1.63	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.